New Vaccine Partnership With GSK Could Act As Lifeline For Chinese Biotech Firm Neptunus, Which Has Been Trapped In Troubled Financial Seas
This article was originally published in PharmAsia News
Executive Summary
BEIJING - A new vaccine joint venture with the United Kingdom's GlaxoSmithKline could become a lifesaver for the Chinese biologics outfit Shenzhen Neptunus Interlong Bio-Technique Co., which has been fighting to stay afloat amid a maelstrom of earnings losses, staff layoffs and a partial halt in production
You may also be interested in...
Technology Transfers To Least-Developed Countries Often Not An Option - IFPMA Report
HONG KONG - The transfer of technology developed by high-end research-based pharmaceutical companies to operations in developing countries is increasingly common, but rarely simple
Technology Transfers To Least-Developed Countries Often Not An Option - IFPMA Report
HONG KONG - The transfer of technology developed by high-end research-based pharmaceutical companies to operations in developing countries is increasingly common, but rarely simple
GSK Channels More Money Into Vaccine Venture With China's Neptunus As Earnings Sink In The West
BEIJING - Despite posting a sizeable loss in earnings for the second quarter of this year, GlaxoSmithKline is pumping new funds into its recently established joint venture in southern China in a move aimed at profiting from China's healthy economic growth despite the financial ailments that have plagued the Western world